NASDAQ:SELB Selecta Biosciences (SELB) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free SELB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.88▼$1.2652-Week Range N/AVolume2.77 million shsAverage Volume979,585 shsMarket Capitalization$136.76 millionP/E RatioN/ADividend YieldN/APrice Target$2.80 Stock AnalysisStock Analysis Get Selecta Biosciences alerts: Email Address Selecta Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside∞ Upside$2.80 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.33) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.80 out of 5 starsMedical Sector424th out of 920 stocksBiotechnology Industry1st out of 11 stocks 3.3 Analyst's Opinion Consensus RatingSelecta Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSelecta Biosciences has received no research coverage in the past 90 days.Read more about Selecta Biosciences' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SELB. Previous Next 0.0 Dividend Strength Dividend YieldSelecta Biosciences does not currently pay a dividend.Dividend GrowthSelecta Biosciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSelecta Biosciences has received a 69.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Selecta Biosciences is -0.99. Previous Next N/A News and Social Media Coverage Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Selecta Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of Selecta Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.95% of the stock of Selecta Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Selecta Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Selecta Biosciences are expected to grow in the coming year, from ($0.33) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About Selecta Biosciences Stock (NASDAQ:SELB)Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.Read More Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… SELB Stock News HeadlinesMay 6, 2024 | msn.comCraig David says Leigh Francis' Bo Selecta! skit 'sent him down a dark road'January 23, 2024 | yahoo.comSelb, Germany - Weather Forecasts | Maps | News - Yahoo WeatherDecember 15, 2023 | investing.comCartesian Therapeutics Inc (RNAC)November 14, 2023 | finance.yahoo.comFurther weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%November 13, 2023 | bizjournals.comPared-down Selecta merges with Maryland biotechNovember 13, 2023 | msn.comSelecta Biosciences Merges With Cartesian To Focus On Autoimmune Cell TherapyNovember 13, 2023 | markets.businessinsider.comSelecta Biosciences Merges With Cartesian Therapeutics In All-stock DealNovember 11, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) and Encourages Investors to Contact the FirmNovember 10, 2023 | morningstar.comSelecta Biosciences Inc SELBOctober 31, 2023 | marketwatch.comSelecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 TreatmentOctober 31, 2023 | finance.yahoo.comSelecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner SobiOctober 25, 2023 | msn.comSelecta Biosciences files for $200M mixed shelfAugust 19, 2023 | msn.comMizuho Maintains Selecta Biosciences (SELB) Buy RecommendationAugust 19, 2023 | msn.comSVB Leerink Downgrades Selecta Biosciences (SELB)August 18, 2023 | markets.businessinsider.comAnalyst Ratings for Selecta BiosciencesAugust 18, 2023 | msn.comNeedham Maintains Selecta Biosciences (SELB) Buy RecommendationAugust 18, 2023 | markets.businessinsider.comSelecta Biosciences (SELB) Gets a Buy from H.C. WainwrightAugust 17, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Selecta Biosciences (SELB)August 17, 2023 | finance.yahoo.comQ2 2023 Selecta Biosciences Inc Earnings CallAugust 17, 2023 | msn.comSelecta Biosciences Narrows R&D Focus On Gout CandidateAugust 17, 2023 | finance.yahoo.comSelecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue EstimatesAugust 17, 2023 | finance.yahoo.comSelecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 EconomicsJuly 14, 2023 | finance.yahoo.comSelecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26%June 3, 2023 | finance.yahoo.comSelecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five yearsMay 31, 2023 | finance.yahoo.comSelecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of RheumatologySee More Headlines Receive SELB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/17/2023Today5/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SELB CUSIPN/A CIK1453687 Webselectabio.com Phone(617) 923-1400Fax617-924-3454Employees64Year FoundedN/APrice Target and Rating Average Stock Price Target$2.80 High Stock Price Target$5.00 Low Stock Price Target$1.00 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$35.38 million Net Margins-72.04% Pretax Margin-73.23% Return on Equity-44.13% Return on Assets-22.00% Debt Debt-to-Equity Ratio0.21 Current Ratio4.18 Quick Ratio4.18 Sales & Book Value Annual Sales$110.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.91 Book Value$0.61 per share Price / BookN/AMiscellaneous Outstanding Shares155,200,000Free Float106,780,000Market Cap$136.76 million OptionableOptionable Beta0.84 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Carsten Brunn Ph.D. (Age 52)CEO, President & Director Comp: $914.66kMr. Blaine T. Davis (Age 49)Chief Financial Officer Comp: $370.34kDr. Lloyd Johnston Ph.D. (Age 55)Chief Operating Officer Comp: $589.81kDr. Takashi Kei Kishimoto Ph.D. (Age 63)Chief Scientific Officer Comp: $599.81kDr. Peter G. Traber M.D. (Age 68)Chief Medical Officer Comp: $670.29kDr. Ulrich H. von Andrian-Werburg M.D.Ph.D., Co-Founder and Co-Chair of the Scientific Advisory BoardMr. Matthew Bartholomae J.D.General Counsel & SecretaryMs. Kristen BaldwinChief People OfficerMs. Ann K. Donohue CPA (Age 41)VP of Finance & Controller Comp: $286.97kMore ExecutivesKey CompetitorsLianBioNASDAQ:LIANFitLife BrandsNASDAQ:FTLFRegulus TherapeuticsNASDAQ:RGLSVigil NeuroscienceNASDAQ:VIGLSeres TherapeuticsNASDAQ:MCRBView All CompetitorsInsidersCarsten BrunnSold 2,932 sharesTotal: $3,107.92 ($1.06/share)Peter G TraberSold 705 sharesTotal: $747.30 ($1.06/share) SELB Stock Analysis - Frequently Asked Questions Should I buy or sell Selecta Biosciences stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SELB shares. View SELB analyst ratings or view top-rated stocks. What is Selecta Biosciences' stock price target for 2024? 6 brokers have issued 12 month price objectives for Selecta Biosciences' shares. Their SELB share price targets range from $1.00 to $5.00. On average, they predict the company's stock price to reach $2.80 in the next year. View analysts price targets for SELB or view top-rated stocks among Wall Street analysts. How were Selecta Biosciences' earnings last quarter? Selecta Biosciences, Inc. (NASDAQ:SELB) issued its quarterly earnings results on Thursday, August, 17th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.05. The firm earned $5.25 million during the quarter, compared to the consensus estimate of $9.90 million. Selecta Biosciences had a negative net margin of 72.04% and a negative trailing twelve-month return on equity of 44.13%. What other stocks do shareholders of Selecta Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD). When did Selecta Biosciences IPO? Selecta Biosciences (SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers. This page (NASDAQ:SELB) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Selecta Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.